According to the Ministry of Financial Economic Stabilization and National Policy, the State Pharmaceutical Corporation is set to receive 51.6 billion rupees from the medical supply sector by the end of 2022. However, this influx of funds has brought various financial problems to the institution.
The Ministry of Finance highlights that the State Pharmaceutical Regulatory Corporation has experienced a decline in its average annual revenue growth rate by 15 percent in 2022. This downturn can be attributed to factors such as import restrictions caused by foreign exchange shortages and public finance constraints.
Recognizing the need for improved financial performance, the Ministry of Finance emphasizes the necessity of enhancing the management information systems and procurement methods employed by the Pharmaceutical Corporation. These measures aim to address the challenges faced by the institution and foster positive financial outcomes.
